Adipose-derived stem cells (ASCs) improve the self-renewal and survival of fat grafts in breast reconstruction after oncology surgery. However, ASCs have also been found to enhance breast cancer growth, and its role in tumor proliferation remains largely elusive. Here, we explored a novel mechanism that mediates hTERT reactivation during ASC-induced tumor growth in breast cancer cells. In this study, we found the proliferative ability of breast cancer cells markedly increased with ASC coculture. To explore the molecular mechanism, we treated cells with an antibody/inhibitor and found that the activation of MEK-ERK pathway was triggered in breast cancer cells by SCF secreted from ASCs, leading to the nuclear recruitment of CBP. As a coactivator of hTERT, CBP subsequently coordinated with RFPL-3 upregulated hTERT transcription and telomerase activity. The inhibition of CBP and RFPL-3 abrogated the activation of hTERT transcription and the promotion of proliferation in breast cancer cells with cocultured ASCs in vitro and in vivo. Collectively, our study findings indicated that CBP coordination with RFPL-3 promotes ASC-induced breast cancer cell proliferation by anchoring to the hTERT promoter and upregulating telomerase activity, which is activated by the MAPK/ERK pathway.

1. Introduction

At present, adipose-derived stem cells (ASCs)-assisted lipotransfer are increasingly applied for repairing defects after breast cancer surgery because of their regenerative properties [1]. However, the results that ASCs might promote breast cancer growth have been demonstrated in our previous study [2], and the precise mechanisms that govern tumor growth are still being elucidated.

The stem cell factor (SCF)/c-kit axis plays critical roles in the tumor environment [3]. Binding of SCF to transmembrane protein c-kit causes the cascade activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways [4], in which phosphorylated extracellular-regulated protein kinase (ERK) translocates to the nucleus and stimulates transcription factor activity, including that of cAMP-response element-binding protein (CREB), which is generally involved in cell differentiation and proliferation [5, 6]. CBP, as the binding protein of CREB, can form a bridge with other transcription factors and activate transcription by acetylating histones and other regulatory proteins in tumourigenesis [7]. It has been reported that cancer-associated adipose tissue secretomes activate CBP [8]. However, at present, no data support the hypothesis that CBP is activated by the MAPK/ERK signaling pathway or coordinated with other transcription factors to regulate the ASC’s tumor-promoting effect in breast cancer growth.
Telomerase, a reverse transcriptase that endows cells with unlimited chromosome replication, is thought to be crucial for the process of carcinogenesis [9]. Human telomerase reverse transcriptase (hTERT) is a critical subunit of telomerase, and its ectopic expression is involved in tumor proliferation, metastasis, and sensitivity to chemoradiotherapy [10, 11]. Accumulating evidence demonstrates that numerous transcription factors are involved in regulating the activity of the hTERT promoter [12]; however, the breast cancer-specific activation mechanisms of hTERT during tumourigenesis remain unclear. Members of the ret finger protein-like (RFPL) protein family, similar to the ret finger protein, are involved in regulating the cell cycle and embryonic development [13]. The RFPL-3 gene is located proximal to telomeres, and the protein has special structural characteristics, such as a tripartite structure and the absence of a DNA-binding domain, which enable it to mediate protein-protein interactions but not bind to target gene promoters [14]. Previous research has reported that RFPL-3 could activate the hTERT promoter and promote the growth of human lung cancer cells, especially in coordination with CBP [15, 16]. However, the precise mechanisms of the CBP regulation of RFPL3-mediated hTERT activity and proliferation of breast cancer cells remain unknown, especially regarding the action of ASCs.

In this study, we found that ASCs promoted the proliferation of breast cancer cells. Mechanistically, we demonstrate that the activated MEK-ERK pathway mediated the nuclear recruitment of CBP in breast cancer cells cocultured with ASCs. Furthermore, CBP coordinated with RFPL-3 to subsequently activate hTERT transcription and telomerase activity. The inhibition of CBP and RFPL-3 suppressed the proliferation of breast cancer cells cocultured with ASCs following decreases in hTERT transcriptional activity in vitro and in vivo. Altogether, our study reveals a new regulatory mechanism and provides a new therapeutic target for treating breast cancer.

2. Method

2.1. Cell Lines, Stable Cell Lines, and Inhibitors. The MCF-10A, SKBR-3, MCF-7, and MDA-MB-231 cell lines were purchased from ATCC (Manassas, VA, USA). The medium was obtained from HyClone supplemented with 10% FBS (Gibco, USA). ASCs were prepared as our previous description [3]. Briefly, the pelleted cells were washed twice using PBS and labeled with rabbit polyclonal anti-c-kit antibody (Abcam, USA) and goat anti-rabbit IgG magnetic beads (Miltenyi Biotech Inc., USA). Anti-c-kit-labeled cells were further purified by fluorescence-activated cell sorting. The cells were incubated in 37°C humidified incubator containing 5% CO₂ and the medium was replaced for 2-3 days.

The scrambled nontarget control shRNA- or hTERT-expressing lentiviruses and the lentivirus particles for CBP short-hairpin RNA (shRNA) were purchased from GenePharma (Shanghai, China). The breast cancer cell lines were cotransfected with CBP shRNA and the hTERT-expressing lentivirus to rescue hTERT expression. Selumetinib and SP600125 (Selleckchem, USA) were diluted using DMSO to the final concentrations of 1 μM and 10 μM, respectively. SCF (R&D, USA) was used at a final concentration of 100 ng/ml.

2.2. Cell Viability Assay. Breast cancer cells were transfected with siRNA-CBP oligonucleotides or siRNA-RFPL3 oligonucleotides for 48 hours. In addition, Cells stably expressing CBP were treated with RFPL-3 siRNA or control siRNA, and the cells overexpressing RFPL-3 were cotransfected with CBP siRNA or control siRNA for 48 hours. Then, the cells (3 x 103 per well) were seeded into 96-well plates and cultured with the culture supernatant from ASCs for 24-96 hours. Thereafter, 10 μl of CCK-8 solution per well was added, and the cells were further incubated for 3 h. The absorbance was measured using a microplate reader at 450 nm.

2.3. Cell Proliferation Assay. The cell proliferation was assessed by using dsDNA quantitation according to manufacturer’s protocols as previously described [2]. After being cultured in the culture supernatant from ASCs for 24-96 hours, the transacted cells, including being transfected with siRNA-CBP oligonucleotides or siRNA-RFPL3 oligonucleotides, were washed with PBS and digested using Triton X-100. Then, the samples were centrifuged, the PicoGreen fluorescent reagent was added to the supernatant, and samples were transferred to 96-well plates. Fluorescence was detected with NanoDrop 3300 (Thermo Scientific, USA), and the dsDNA values were calculated according to known DNA standard curve.

2.4. Colony Formation Assays. The breast cancer cells (2 x 10⁴ per well) were cultured in 6-well plates with culture supernatant from ASCs. After 2 weeks, the colonies were fixed in MeOH and stained with crystal violet (Sigma, USA) for 30 min separately for counting.

2.5. Quantification of Cytokines/Chemokine. After being cultured for 1, 3, and 5 days, the cell culture supernatant was obtained and was simultaneously detected with MILLIPLEX MAP mouse cytokine/chemokine panel (Cat.MAGPMAG-24K, Millipore Corporation, USA) as previously described [17].

2.6. Immunofluorescence. Attached cells plated on 24-well plates were incubated with rat monoclonal to RFPL-3 (Abcam, USA) and donkey secondary antibody to rat (Alexa Fluor 488, Thermo Scientific, USA). Then, the cells were labeled with rabbit polyclonal to CBP (Abcam) and incubated with goat secondary antibody to rabbit (Alexa Fluor 647, Abcam). After being stained with DAPI for 1 min, the positive cells were observed using the confocal microscopy system (Yokogawa, Tokyo, Japan).

2.7. Transient Transfection. The vector including RFPL-3-expressing vectors, control vectors (GenePharma, Shanghai, China), and siRNA including RFPL-3 siRNA or nonspecific siRNA (GenePharma) were transfected into breast cancer cells using Lipofectamine 3000 (Invitrogen, USA) according to the manufacturer’s protocol. In addition, breast cancer
cells were transfected with pcDNA3.1-CBP or empty vector plasmids and CBP siRNA or nonspecific siRNA. After 48 hours, mRNA and protein were extracted, and telomerase activity was detected.

2.8. Dual-Luciferase Assay. Breast cancer cells overexpressing CBP and transfected with RFPL-3 siRNA or control siRNA were seeded into 96-well plates, and the telomerase plasmid including hTERT promoter was cotransfected into cells. In addition, the luciferase reporter plasmid was cotransfected into MDA-MB-231 cells stably expressing RFPL-3 and treated with control siRNA or CBP siRNA (Table S1). After twenty-four hours, cells were collected, and luciferase activity was analyzed as previously described [17].

2.9. RNA Extraction and qPCR. Total RNA (1 μg) was extracted and reverse-transcribed into cDNA, and qPCR was performed as described before [3]. Amplification conditions were as follows: 95°C for 3 min (pre-denaturation), 35 cycles of denaturation at 95°C for 10 s, and extension at 60°C for 30 s (Table S2). The expression levels were analyzed with the 2^−ΔΔCt method.

2.10. Western Blotting. The protein samples were extracted and immunoblotted with primary antibodies against RFPL-3 (1:2000), hTERT (1:1000), CBP (1:1000), ERK1/2 (1:1000), p-ERK1/2 (pT202/pY204, 1:1000), c-JUN (1:2000), and p-cJUN (Ser63, 1:1000), overnight at 4°C, the secondary antibodies were incubated at room temperature for 2 h, and the protein bands were visualized using an enhanced chemiluminescence detection kit (Beyotime Biotechnology, China) and western blot imaging system (Bio-Rad, USA).

2.11. Animal Studies. All the animal experiments were approved by the Animal Ethics Committee of Harbin Medical University. The BALB/c female nude mice aged four weeks were acquired from the Shanghai SLAC Laboratory Animal Co. All the care and use of experimental animals were in compliance with the National Institutes of Health’s Guidelines. To establish the xenograft model, the 4-week-old BALB/c female nude mice (n = 5/group) were anesthetized with 1.2% Avertin (0.1 ml/10 g) and performed with 1% formaldehyde for 10 min and incubated with RFPL-3, CBP or IgG antibody. The 10% chromatin was used for the DNA input. The extracted DNA was assessed by PCR, and the primers as follows: hTERT, 5'-TGGCCC CTCCCTCCGGTTAC-3', and 5'-CCAGGGCITTCCCCAC GTGGCGC-3'. The amplified product was analyzed by agarose gel electrophoresis.

2.12. ChIP Immunoprecipitation Assay. ChIP assays were performed as previously described [17]. In brief, the chromatin samples was sonicated from the cells after being fixed with 1% formaldehyde for 10 min and incubated with RFPL-3, CBP or IgG antibody. The 10% chromatin was used for the DNA input. The extracted DNA was assessed by
Figure 1: Continued.
3.2. MAPK-ERK Signaling Mediates the ASC-Stimulated Proliferation of Breast Cancer Cells by CBP Recruitment.

SCF, as the only known kit ligand, binds to the c-kit receptors and subsequently activates a series of downstream pathways including the MAPK pathways [18]. Therefore, we examined whether the pathways were activated in MDA-MB-231 cells treated with SCF and found that phosphorylated ERK (p-ERK) triggered CBP upregulation.
Next, to further clarify the role of the MAPK-ERK pathway to CBP recruitment in the ASC-induced proliferation of breast cancer cells, we incubated the MDA-MB-231 cells with a MEK inhibitor, a JNK inhibitor, and an anti-SCF antibody and analyzed the changes in p-ERK and CBP expression levels using western blot. The results demonstrated that an anti-SCF antibody significantly inhibited the CBP expression levels in the nuclei following the phospho-ERK1/2 decrease (Figures 2(b) and 2(c)). Moreover, treatment with MEK inhibitor decreased the ASC-stimulated CBP expression in MDA-MB-231 cells (Figure 2(c)). Interestingly, the JNK inhibitor did not significantly result in the inhibition of CBP expression in the nuclei (Figure 2(c)). Furthermore, the ASC-stimulated viability and proliferation of breast cancer cells were abrogated by the anti-SCF antibody and MEK inhibitor (Figures 2(d) and 2(e), Figure S3A–B).

These results indicated that the SCF-MEK-ERK pathways activated CBP recruitment, which might mediate the ASC-stimulated proliferation of breast cancer cells.

3.3. CBP Coordination with RFPL-3 Activates the hTERT Transcription in Breast Cancer Cells. It has been reported that CBP, as a transcriptional coactivator, could coordinate with RFPL-3 and regulate the hTERT transcriptional activation in lung cancer [16], and our results shown higher expression levels of RFPL-3 in the indirect coculture of MDA-MB-231 cells with ASCs (Figure 3(a)) and shown that RFPL-3 was localized in the nuclei of MDA-MB-231 cells, with CBP (Figure 3(b)). To further investigate whether CBP coordinated with RFPL-3 to regulate hTERT transcription, cotransfection was performed with an hTERT promoter-driven luciferase plasmid and nonspecific siRNA, RFPL-3-specific siRNA or RFPL-3-

(Figure 2(a), Figure S2).
specific siRNA in MDA-MB-231 cells, and SKBR-3 stably expressing CBP. We found that overexpression of CBP markedly increased hTERT upregulation, but RFPL-3 knockdown downregulated the elevated expression of hTERT without affecting CBP expression (Figure 3(c)). Similarly, the RFPL-3 knockdown caused a decline in hTERT promoter activity in MDA-MB-231 and SKBR-3 cells with CBP overexpression (Figure 3(d), Figure S4A). By contrast, the knockdown of CBP markedly decreased the hTERT upregulation caused by RFPL-3 overexpression but had no effect on the expression of RFPL-3 (Figure 3(e)). Furthermore, cells with CBP knockdown showed significantly attenuated hTERT promoter activity compared with cells overexpressing RFPL-3 (Figure 3(f), Figure S4B). These results suggested that CBP coordination with RFPL-3 activates the hTERT transcriptional activity in breast cancer cells.

3.4. Depletion of CBP and RFPL-3 Inhibits the ASC-Induced Breast Cancer Cells Proliferation by Downregulating hTERT Expression In Vitro and In Vivo. To further confirm whether CBP and RFPL-3 activated hTERT transcription, CBP-
Figure 4: Continued.
Figure 4: Inhibition of CBP and RFPL-3 suppresses the proliferation of breast cancer cells with cocultured ASCs following decreases in hTERT transcription in vitro and in vivo. (a) Real-time PCR and western blot analysis of the expression of hTERT mRNA and protein in MDA-MB-231 cells transfected with CBP siRNA and nonspecific siRNA. (b–c) The transfected MDA-MB-231 cells were treated with culture supernatant from ASCs, and the cell viability and proliferation were analyzed using CCK-8 assays and dsDNA quantification. (d) MDA-MB-231 cells were transfected with RFPL-3 siRNA and nonspecific siRNA, and then, hTERT mRNA and protein were examined using real-time-PCR and Western blot. (e–f) MDA-MB-231 cells transfected as above were treated with culture supernatant from ASCs, and then, the cell viability and proliferation were examined by CCK-8 assays and dsDNA quantification. (g) Tumor grafts up to 21 days after nude mice were injected with ASCs and cell lines stably expressing CBP shRNA, scramble shRNA, CBP shRNA + empty vector, and CBP shRNA + hTERT. (h) Tumor growth curves in nude mice. (i) The mean tumor weights 21 days after coinjection. (j) Western blot analysis of the expression of CBP and hTERT in tumor xenografts. *P < 0.05, **P < 0.01, ***P < 0.001.
specific siRNA or RFPL-3-specific siRNA was used to knock down CBP or RFPL-3 expression, respectively, in SKBR-3 and MDA-MB-231 breast cancer cells. As shown in Figure 4(a) and Figure S5A, the downregulation of CBP results in a significant decrease in hTERT expression in MDA-MB-231 breast cancer cells. Besides, silencing CBP suppressed the ASC-induced proliferation in breast cancer cells (Figures 4(b) and 4(c), Figure S5B–C). Meanwhile, the inhibition of RFPL-3 led to the marked downregulation of hTERT expression and the promotion of proliferation in breast cancer cells cocultured with ASCs (Figures 4(d)–4(f), Figure SSD–F).

As a coactivator of hTERT, CBP was clearly involved in the ASC-induced proliferation of breast cancer cells in vitro; to further explore the mechanisms involved in the process of ASC-induced tumor growth, we constructed a series of stable cell lines expressing CBP shRNA, scramble shRNA, CBP shRNA + empty vector, or CBP shRNA + hTERT and performed subcutaneous coinjection of these cells and ASCs into nude mice. The results show that tumor growth was inhibited by the blockade of CBP in the mouse model (Figures 4(g)–4(i)). However, overexpression of hTERT in combination with CBP knockdown partially restored the tumor growth (Figures 4(g)–4(i)). The results were confirmed by western blots using xenograft tumor tissue (Figure 4(j)). Taken together, our findings clearly demonstrate that the depletion of CBP and RFPL-3 inhibits ASC-induced proliferation of breast cancer cells through the suppression of hTERT.

3.5. ASC Induction of CBP Upregulation Enhances Telomerase Activity by Activating the Binding of RFPL-3 to the hTERT Promoter Region in Breast Cancer Cells. A previous study showed that RFPL-3 could bind to the hTERT promoter in lung cancer cells [15]. Accordingly, to detect the proteins on the hTERT promoter, we performed a ChIP assay and found that the RFPL-3 proteins bound to the hTERT promoter in breast cancer cells cocultured with ASCs (Figures 4(d)–4(f), Figure SSD–F).

**Figure 5:** ASC induction of CBP upregulation enhances telomerase activity by activating the binding of RFPL-3 to the hTERT promoter region in breast cancer cells. (a) Chromatin immunoprecipitation assays were performed using anti-RFPL3 in normal breast cells and breast cancer cells. The amplified products of the hTERT promoter were analyzed by agarose gel electrophoresis. IgG was used as a negative control. (b) Chromatin immunoprecipitation analysis of the proteins bound to the hTERT promoter was performed using anti-CBP in breast cancer cells, and then, the pulled-down protein complex was examined by immunoblotting using anti-CBP. (c) The immunoprecipitation assay of nuclear extracts from breast cancer cells was carried out using anti-RFPL3, and then, the complexes were analyzed by immunoblotting using anti-CBP. (d–e) Chromatin immunoprecipitation analysis of the proteins bound to the hTERT promoter was performed using anti-RFPL3 and anti-CBP in breast cancer cells cocultured with ASCs. (f) The telomerase activity in MDA-MB-231 cells transfected with CBP vectors was measured using a TeloTAGGG telomerase PCR ELISAs. \(*P < 0.01\).
promoter region in breast cancer cells, especially MDA-MB-231 cells, were higher than that in normal breast cells (Figure 5(a), Figure S6A). In addition, we also found by immunoprecipitation and pull-down analysis that CBP did indeed bind to the hTERT promoter and interact directly with RFPL-3 (Figures 5(b) and 5(c), Figure S6B). And, we found that the binding of RFPL-3 and CBP to the hTERT promoter was significantly increased in the MDA-MB-231 cells cocultured with ASCs compared to that in the untreated cells (Figures 5(d) and 5(e), Figure S6C–D). These results indicated that ASC induction of CBP upregulation mediated the binding of RFPL-3 to the hTERT promoter in breast cancer cells. To further examine whether the upregulation of CBP activated telomerase activity, the TeloTAGGG telomerase PCR ELISA was performed in MDA-MB-231 cells stably expressing CBP. The overexpression of CBP markedly upregulated the telomerase activity in MDA-MB-231 cells (Figure 5(f)). These results confirmed that p-ERK is positively associated with SCF and CBP in ASC-induced breast cancer cell proliferation. CBP can bind with transcription factors and activate transcription by acetylating histones and other regulatory proteins in tumourigenesis [26]. Meanwhile, RFPL-3 protein, which are most similar to the ret finger protein, contains RING, B30-2, and coiled-coil domains and interacts with other transcription factors [14]. Previous research has reported a synergistic effect of CBP and RFPL-3 in lung cancer [16]. Given this background, we explored whether CBP and RFPL-3 could coregulate hTERT transcription in the ASC-stimulated breast cancer cell proliferation. In line with our hypothesis, the results showed that overexpressed CBP did indeed regulate the ASC-stimulated breast cancer cell proliferation by activating the binding of RFPL-3 to the hTERT promoter region and enhancing telomerase activity.

4. Discussion

ASCs, with the abilities of differentiation and regeneration, have the potential to affect tumor growth after mastectomy [19], and we have reported that ASCs can favor tumourigenesis in breast cancer in our previous study [2]; however, it is not clear about the precise molecular mechanisms. The c-kit signaling network is involved in cell differentiation and proliferation [20], and the expression of SCF/c-kit is upregulated in the process of ASC-stimulated proliferation of breast cancer cell [2]. The activation of SCF/c-kit axis triggers cascade of MAPK pathways [21], of which the ERK pathway is generally responsible for cell differentiation and proliferation, whereas the JNK pathway is involved in apoptosis [22]. Additionally, the phospho-ERK translocation from the cytoplasm to the nucleus stimulates the activity of transcription factors such as STAT1/3, Pax6, and CREB [23–25]. In addition, CBP expression is markedly increased in breast cancer cells treated with cancer-associated adipose tissue [8]. Our results clearly confirmed that p-ERK is positively associated with SCF and CBP in ASC-induced breast cancer cell proliferation.

Cancer cells

ASCs

SCF

C-kit

Cytoplasm

Nucleus

Cancer cells

Figure 6: Overview of the proposed pathways for ASCs-induced proliferation of breast cancer cells.
Telomerase is involved in tumourigenesis-related signaling pathways in addition to telomere maintenance [27]. Telomerase reactivation or upregulation is governed by telomerase reverse transcriptase (TERT) expression [28, 29]. The hTERT promoter core contains GC boxes (GGGCGG) and E boxes (5′-CACGTG-3′), which provide binding sites for multiple transcription factors [30]. Some enhancer-binding proteins, such as zinc finger transcription factors, NF-xB and c-Myc, bind to their respective sites and regulate hTERT transcription in different cellular contexts [31]. Herein, we only explore the role of CBP, not RFPL-3 in vivo because we find that the RFPL-3 protein cannot fully regulate hTERT expression, suggesting that other factors may regulate proliferation, such as the transcription factor activator protein-2 (AP-2), which is expressed in many human breast cancer cell lines and can activate c-erbB-2 and estrogen receptor promoters and increase their proliferation [32], or the others factors interfere with the function of RFPL-3, such as the Importin 13 (IPO13) can mediate the nuclear import of RFPL-3 through a functional NLS within RFPL-3 and subsequent hTERT expression upregulation [33].

In summary, our findings have shown that CBP coordinates with RFPL-3 to promote ASC-induced breast cancer cell proliferation by anchoring to the hTERT promoter and upregulating telomerase activity, which is activated by the MAPK/ERK signaling pathway (Figure 6). Hence, our studies uncover that the interference with MAPK/ERK/CBP-RFPL-3/hTERT pathway may be used as a potential therapeutic strategy to reduce ASC-stimulated proliferation of breast cancer cells.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Wenjie Li has contributed to the conceptualization of the study. Wenjie Li and Cheng Qian have contributed to the methodology of the study. Wenjie Li has contributed to the validation of the study. Wenjie Li, Fei Ma, and Meng Liu have contributed to the formal analysis of the study. Wenjie Li and Haiqian Xu have contributed to the investigation of the study. Fei Ma and Meng Liu have contributed to the resources of the study. Wenjie Li, Xiaojun Sun, Xu Liu, and Chunxiao Liu have contributed to the data curation of the study. Wenjie Li has contributed to the writing to original draft preparation. Wenjie Li, Cheng Qian, Zhenlin Yang, and Haiqian Xu have contributed to the writing-review and editing. Wenjie Li, Weichang Ma, Jian Liu, and Zhenghua Chen have contributed to the visualization of the study. Haiqian Xu has contributed to the supervision of the study. Wenjie Li and Haiqian Xu have contributed to the project administration. All authors read and approved the final version of the manuscript.

Acknowledgments
This work was supported by the Research and Innovation Foundation of The First Affiliated Hospital of Harbin Medical University (2018B014) and the Scientific Research Foundation of Binzhou Medical University. The work was supported by the Medical and Health Science and Technology Development Plan of Shandong Province (202104080969).

Supplementary Materials
The supplementary including the results in SKBR-3 breast cancer cells and the density analysis in western blot and CHIP assay. Figure S1: ASCs promote the viability, proliferation and colony formation of SKBR-3 breast cancer cells following the release of cytokines and chemokines. (A–C) Cell viability, proliferation, and colony formation were analyzed using CCK-8 assays, dsDNA quantification, and colony formation assays in SKBR-3 cells treated with culture supernatant from ASCs. (D) The release of cytokines and chemokines including SCF, IL-6, sCD31, MCP-1, MIP-1α, SDF-1, VEGFA, and TNFa in SKBR-3 cells cocultured five days with ASCs was analyzed using Milliplex MAP kit. *P < 0.05, **P < 0.01, ***P < 0.001, NS: no significance. Figure S2: The expression of phosphorylated ERK and CBP in MDA-MB-231 cells treated with SCF (1 ng/ml). (A–B) Density assay shows the expression of p-ERK1/2 and CBP in MDA-MB-231 cells were activated by c-Kit + ASCs using Image-Pro Plus 6.0 software. *P < 0.05. Figure S3: The SKBR-3 cells were pretreated with IgG or anti-SCF-neutralizing antibody for 1 h, 1 μM selumetinib (MEKi), and 10 μM SP600125 (JNKi) for 24 hours, and then, the cells’ viability (A) and proliferation (B) were analyzed. The results were normalized, the cells that were treated with IgG were used as a positive control, and the value was set to 1. *P < 0.05, **P < 0.01. Figure S4: CBP coordinated with RFPL-3 to coregulate hTERT transcriptional activity in breast cancer cells. (A) The SKBR-3 cells with CBP upregulation were cotransfected with RFPL-3 siRNA or control siRNA and hTERT-luciferase plasmids, and the relative luciferase activity was examined. (B) CBP-specific siRNA and hTERT promoter-driven luciferase plasmids were cotransfected into SKBR-3 cells overexpressing RFPL-3, and then, the relative luciferase activity was analyzed in the cells. *P < 0.01, **P < 0.001. Figure S5: Inhibition of CBP and RFPL-3 suppresses the proliferation of breast cancer cells cocultured with ASCs following decreases in hTERT transcription. (A) Real-time PCR and western blot analysis of the expression of hTERT mRNA and protein in SKBR-3 cells transfected with CBP siRNA and nonspecific siRNA. (B–C) The transfected SKBR-3 cells were treated with culture supernatant from ASCs, and the cell viability and proliferation were analyzed using CCK-8 assays and dsDNA quantification. (D) SKBR-3 cells were transfected with RFPL-3 siRNA and nonspecific siRNA, and then,
hTERT mRNA and protein were examined using real-time PCR and western blot. (E–F) SKBR-3 cells transfected as above were treated with culture supernatant from ASCs, and then, the cell viability and proliferation were examined by CCK-8 assays and dsDNA quantification. Figure S6: Density analysis of the ChIP data. (A–B) Density assay shows the binding of RFPL-3 and CBP proteins on the hTERT promoter region in MDA-MB-231 breast cancer cells and was higher than that in MCF-7 and SKBR-3 breast cancer cells in ChIP assay. (C–D) The relative densities of the binding of RFPL-3 and CBP to the hTERT promoter in Figures 5(d) and 5(e) were analyzed using Image-Pro Plus 6.0 software. **P < 0.01, ***P < 0.001. Table S1 The sequence of RNA oligonucleotides or shRNA. Table S2 The sequence of primer. Table S3 The release of cytokines in MDA-MB-231( Supplementary Materials)

References

[1] C. Brown, C. McKee, S. Bakshi et al., “Mesenchymal stem cells: cell therapy and regeneration potential,” Journal of Tissue Engineering and Regenerative Medicine, vol. 13, no. 9, pp. 1738–1755, 2019.

[2] W. Li, H. Xu, and C. Qian, “c-kit-positive adipose tissue-derived mesenchymal stem cells promote the growth and angiogenesis of breast cancer,” BioMed Research International, vol. 2017, Article ID 7407168, 12 pages, 2017.

[3] J. O. Kim, H. N. Kim, K. H. Kim et al., “Development and characterization of a fully human antibody targeting SCF/c-kit signaling,” International Journal of Biological Macromolecules, vol. 159, pp. 66–78, 2020.

[4] C. Bai, Y. Xu, and C. Qiu, “A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth,” Journal of Cancer Research and Clinical Oncology, vol. 147, no. 4, pp. 1065–1075, 2021.

[5] P. Kumari, H. Dwivedi, M. Baidya, and A. K. Shukla, “Measuring agonist-induced ERK MAP kinase phosphorylation for G-protein-coupled receptors,” Methods in Cell Biology, vol. 149, pp. 141–153, 2019.

[6] J. Ostojić, Y. S. Yoon, T. Sonntag et al., “Transcriptional co-activator regulates melanocyte differentiation and oncogenesis by integrating cAMP and MAPK/ERK pathways,” Cell Reports, vol. 35, no. 7, article 109136, 2021.

[7] L. Sapio, A. Salzillo, A. Ragone, M. Illiano, A. Spina, and S. Naviglio, “Targeting CREB in cancer therapy: a key candidate or one of many? An update,” Cancers (Basel), vol. 12, no. 11, p. 3166, 2020.

[8] A. Jablonka, J. Scheich, F. Jacobsen et al., “Influence of preadipocyte-conditioned medium on the proliferation and invasive potential of breast cancer cell lines in vitro,” Archives of Gynecology and Obstetrics, vol. 298, no. 6, pp. 1159–1171, 2018.

[9] N. Relitti, A. P. Saraswati, S. Federico et al., “Telomerase-based cancer therapeutics: a review on their clinical trials,” Current Topics in Medicinal Chemistry, vol. 20, no. 6, pp. 433–457, 2020.

[10] A. El-Badawy, N. I. Ghoneim, M. A. Nasr et al., “Telomerase reverse transcriptase coordinates with the epithelial-to-mesenchymal transition through a feedback loop to define properties of breast cancer stem cells,” Biology Open, vol. 7, 2018.

[11] E. Rampazzo, P. Del Bianco, R. Bertorelle et al., “The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients,” British Journal of Cancer, vol. 118, no. 6, pp. 878–886, 2018.

[12] N. Liu, X. H. Guo, J. P. Liu, and Y. S. Cong, “Role of telomerase in the tumour microenvironment,” Clinical and Experimental Pharmacology & Physiology, vol. 47, no. 3, pp. 357–364, 2020.

[13] J. Bonnefont, T. Laforge, O. Plastre et al., “Primate-specific RFPL1 gene controls cell-cycle progression through cyclin B1/Cdk2 degradation,” Cell Death and Differentiation, vol. 18, no. 2, pp. 293–303, 2011.

[14] J. Bonnefont, S. I. Nikolaev, A. L. Perrier et al., “Evolutionary forces shape the human RFPL1.2,3 genes toward a role in neocortex development,” American Journal of Human Genetics, vol. 83, no. 2, pp. 208–218, 2008.

[15] W. Chen, J. Lu, Y. Qin et al., “Ret finger protein-like 3 promotes tumor cell growth by activating telomerase reverse transcriptase expression in human lung cancer cells,” Oncotarget, vol. 5, no. 23, pp. 11909–11923, 2014.

[16] Y. Qin, W. Chen, Y. Xiao et al., “RFPL3 and CBP synergistically upregulate hTERT activity and promote lung cancer growth,” Oncotarget, vol. 6, no. 29, pp. 27130–27145, 2015.

[17] H. Xu, W. Li, S. Luo, J. Yuan, and L. Hao, “Adipose derived stem cells promote tumor metastasis in breast cancer cells by stem cell factor inhibition of miR20b,” Cell Signalling, vol. 62, article 109350, 2019.

[18] B. Su, T. Huang, Y. Jin, H. Yin, H. Qiu, and X. Yuan, “Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways,” Gastric Cancer, vol. 24, no. 2, pp. 352–367, 2021.

[19] M. G. Scioli, G. Storti, F. D’Amico et al., “Adipose-derived stem cells in cancer progression: new perspectives and opportunities,” International Journal of Molecular Sciences, vol. 20, no. 13, p. 3296, 2019.

[20] J. Xu, J. Zheng, and X. Fu, “A juxtacrine/paracrine loop between C-kit and stem cell factor promotes cancer stem cell survival in epithelial ovarian cancer,” Cell Death & Disease, vol. 10, no. 6, p. 412, 2019.

[21] J. U. Kazi, M. Vaapil, S. Agarwal, E. Bracco, S. Pahlman, and L. Rönnstrand, “The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling,” Cellular Signalling, vol. 25, pp. 1852–1860, 2013.

[22] Y. J. Guo, W. W. Pan, and S. B. Liu, “ERK/MAPK signalling pathway and tumorigenesis,” Experimental and Therapeutic Medicine, vol. 19, no. 3, pp. 1997–2007, 2020.

[23] Y. Chen, H. Fu, Y. Zhang, and P. Chen, “Transmembrane and ubiquitin-like domain containing 1 protein (TMUB1) negatively regulates hepatocellular carcinoma proliferation via regulating signal transducer and activator of transcription 1 (STAT1),” Medical Science Monitor, vol. 25, pp. 9471–9482, 2019.

[24] D. M. Wu, T. Zhang, Y. B. Liu et al., “The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling,” Cell Death & Disease, vol. 10, no. 5, p. 349, 2019.
[25] C. Zhang, J. Zhang, Q. Wu et al., "Sulforaphene induces apoptosis and inhibits the invasion of esophageal cancer cells through MSK2/CREB/Bcl-2 and cadherin pathway in vivo and in vitro," *Cancer Cell International*, vol. 19, no. 1, p. 342, 2019.

[26] J. Castillo, E. Wu, C. Lowe et al., "CBP/p300 drives the differentiation of regulatory T cells through transcriptional and non-transcriptional mechanisms," *Cancer Research*, vol. 79, no. 15, pp. 3916–3927, 2019.

[27] S. Bajaj, M. S. Kumar, G. J. Peters, and Y. C. Mayur, "Targeting telomerase for its advent in cancer therapeutics," *Medicinal Research Reviews*, vol. 40, no. 5, pp. 1871–1919, 2020.

[28] S. Ghareghomi, S. Ahmadian, N. Zarghami, and H. Kahroba, "Fundamental insights into the interaction between telomerase/TERT and intracellular signaling pathways," *Biochimie*, vol. 181, pp. 12–24, 2021.

[29] S. Grill and J. Nandakumar, "Molecular mechanisms of telomere biology disorders," *Journal of Biological Chemistry*, vol. 296, article 100064, 2021.

[30] A. T. Ludlow, A. L. Slusher, and M. E. Sayed, "Insights into telomerase/hTERT alternative splicing regulation using bioinformatics and network analysis in cancer," *Cancers*, vol. 11, no. 5, p. 666, 2019.

[31] S. G. Fernandes, R. Dsouza, G. Pandya et al., "Role of telomeres and telomeric proteins in human malignancies and their therapeutic potential," *Cancers*, vol. 12, no. 7, p. 1901, 2020.

[32] M. Raap, L. Gierendt, H. H. Kreipe, and M. Christgen, "Transcription factor AP-2beta in development, differentiation and tumorigenesis," *International Journal of Cancer*, vol. 149, no. 6, pp. 1–7, 2021.

[33] B. A. Zohud, P. Guo, B. A. Zohud et al., "Importin 13 promotes NSCLC progression by mediating RFPL3 nuclear translocation and hTERT expression upregulation," *Cell Death & Disease*, vol. 11, no. 10, p. 879, 2020.